

Contents

ABOUT THE EDITORS — v

HISTORICAL DEVELOPMENT
AND PERSPECTIVES OF THE SERIES — vii

PREFACE TO VOLUME 18 — ix

CONTRIBUTORS TO VOLUME 18 — xix

TITLES OF VOLUMES 1–44 IN THE
METAL IONS IN BIOLOGICAL SYSTEMS SERIES — xxiii

CONTENTS OF VOLUMES IN THE
METAL IONS IN LIFE SCIENCES SERIES — xxv

Imogen A. Riddell and Stephen J. Lippard

**1 CISPLATIN AND OXALIPLATIN: OUR CURRENT
UNDERSTANDING OF THEIR ACTIONS — 1**

Abstract — 2

1. Introduction — 2

2. Cellular Uptake and Efflux/Membrane Transport — 6

3. Covalent Adducts Generated with Platinum Agents — 13

4. Cellular Processing of Platinum DNA Adducts — 18

5. Signal Transduction Pathways Activated by Platinum DNA
Damage — 25

6. Undesired Consequences of Platinum-Based Chemotherapy — 30

7. Concluding Remarks and Future Directions — 33

Acknowledgments — 34

Abbreviations and Definitions — 34

References — 35

Viktor Brabec, Jana Kasparkova, Vijay Menon, and Nicholas P. Farrell

**2 POLYNUCLEAR PLATINUM COMPLEXES. STRUCTURAL
DIVERSITY AND DNA BINDING — 43**

Abstract — 44

1. Introduction — 44

2. Dinuclear Bifunctional Platinum(II) Complexes with Alkanediamine Linkers — **46**
3. Polyamine-Linked Bifunctional Dinuclear Platinum(II) Complexes — **49**
4. DNA-Protein Crosslinking — **53**
5. Dinuclear Platinum(II) Complexes Stabilizing G-DNA Quadruplexes — **53**
6. Structural Variation in Dinuclear Platinum(II) Complexes — **55**
7. Trinuclear Platinum(II) Complexes — **56**
8. Conclusions and Outlook — **62**
- Acknowledgments — **63**
- Abbreviations and Definitions — **63**
- References — **64**

V. Venkatesh and Peter J. Sadler

3 PLATINUM(IV) PRODRUGS — 69

Abstract — **70**

1. Introduction — **70**
2. Interactions with Biomolecules — **77**
3. Design Features for Anticancer Complexes — **80**
4. Photoactivatable Complexes — **88**
5. Nano Materials for Drug Delivery — **92**
6. Concluding Remarks — **101**

Acknowledgments — **102**

Abbreviations — **102**

References — **103**

*Nicholas P. Farrell, Anil K. Gorle,
Erica J. Peterson, and Susan J. Berners-Price*

4 METALLOGLYCOMICS — 109

Abstract — **110**

1. Introduction. Metalloglycomics, Heparin, and Heparan Sulfate — **110**
2. Structure and Conformation of Heparin and Heparan Sulfate — **112**
3. Interaction of Metal Ions with Glycosaminoglycans — **118**
4. Interaction of Coordination Compounds with Glycosaminoglycans — **121**
5. Consequences of High-Affinity Heparan Sulfate Binding — **128**
6. Use of Metal Complexes in Heparin Analysis — **134**
7. Conclusions and Outlook — **135**

Acknowledgments — **135**

Abbreviations and Definitions — **135**

References — **136**

Enzo Alessio and Luigi Messori

- 5 THE DECEPTIVELY SIMILAR RUTHENIUM(III) DRUG CANDIDATES KP1019 AND NAMI-A HAVE DIFFERENT ACTIONS. WHAT DID WE LEARN IN THE PAST 30 YEARS? — 141**

Abstract — 142

1. Introduction — 142

2. Comparison of NAMI-A and KP1019 — 145

3. Conclusions and Outlook — 164

Acknowledgments — 165

Abbreviations and Definitions — 165

References — 166

Maria V. Babak and Wee Han Ang

- 6 MULTINUCLEAR ORGANOMETALLIC RUTHENIUM-ARENE COMPLEXES FOR CANCER THERAPY — 171**

Abstract — 172

1. Introduction — 172

2. Homoleptic Dinuclear Complexes — 174

3. Homoleptic Trinuclear and Tetranuclear Complexes — 178

4. Polynuclear Ruthenium-Arene Cages — 181

5. Heteronuclear Ruthenium-Arene Complexes — 186

6. Conclusions — 192

Acknowledgments — 193

Abbreviations — 193

References — 194

Angela Casini, Raymond Wai-Yin Sun, and Ingo Ott

- 7 MEDICINAL CHEMISTRY OF GOLD ANTICANCER METALLODRUGS — 199**

Abstract — 200

1. Introduction — 200

2. Current Status of Registered Gold Drugs — 200

3. Gold(I) Anticancer Drugs — 202

4. Gold(III) Anticancer Drugs — 205

5. Biological Functions of Gold Complexes — 208

6. General Conclusions — 213

Acknowledgments — 213

Abbreviations and Definitions — 214

References — 214

Edit Y. Tshuva and Maya Miller

- 8 COORDINATION COMPLEXES OF TITANIUM(IV) FOR ANTICANCER THERAPY — 219**

Abstract — 219

1. Introduction — 220

2. Cyclopentadienyl-Based Complexes — 221

3. Budotitane and Related Diketonato Complexes — **227**
4. Complexes of Phenolato Ligands — **230**
5. Conclusions and Outlook — **237**
- Acknowledgments — **240**
- Abbreviations and Definitions — **240**
- References — **240**

Debbie C. Crans, Lining Yang, Allison Haase, and Xiaogai Yang

9 HEALTH BENEFITS OF VANADIUM AND ITS POTENTIAL AS AN ANTICANCER AGENT — 251

Abstract — **252**

1. Introduction: Vanadium-Containing Compounds Induce Biological Actions — **252**
2. Applications of Vanadium Compounds in Human Studies — **254**
3. Biological Chemistry of Vanadium — **258**
4. The Anticancer Effects of Vanadium Compounds — **262**
5. Vanadium-Containing Drugs in Context of Other Diseases — **265**
6. Vanadium-Based Drugs and Additives and Their Formulation — **267**
7. Conclusions and Outlook — **272**

Acknowledgments — **273**

Abbreviations — **273**

References — **274**

Christopher R. Chitambar

10 GALLIUM COMPLEXES AS ANTICANCER DRUGS — 281

Abstract — **282**

1. History — **282**
2. Chemistry — **283**
3. Gallium-Based Agents in Clinical Use. Pharmacology and Efficacy — **283**
4. Cellular Handling of Gallium — **288**
5. Antineoplastic Mechanism of Clinically Used Gallium Compounds — **290**
6. Gallium Compounds in Preclinical Development — **294**
7. Summary and Outlook — **296**

Acknowledgments — **297**

Abbreviations — **297**

References — **297**

Lucia Cardo and Michael J. Hannon

11 NON-COVALENT METALLO-DRUGS: USING SHAPE TO TARGET DNA AND RNA JUNCTIONS AND OTHER NUCLEIC ACID STRUCTURES — 303

Abstract — **304**

1. Introduction — **304**
2. Metallo-Cylinders — **304**

- 3. Other Supramolecular Designs and Their Targets — **310**
- 4. Concluding Remarks and Future Directions — **319**
- Acknowledgments — **320**
- Abbreviations and Definitions — **320**
- References — **321**

Ramon Vilar

- 12** NUCLEIC ACID QUADRUPLEXES AND METALLO-DRUGS — **325**
 - Abstract — **325**
 - 1. Introduction — **326**
 - 2. G-Quadruplexes and Their Biological Roles — **327**
 - 3. Metal Complexes as G-Quadruplex Binders — **328**
 - 4. Metal-Based Optical Probes for G-Quadruplexes — **338**
 - 5. Biological Activity of Metal-Based G-Quadruplex Binders — **340**
 - 6. Concluding Remarks and Future Directions — **344**
 - Acknowledgments — **344**
 - Abbreviations — **344**
 - References — **345**

Matthew P. Sullivan, Hannah U. Holtkamp, and Christian G. Hartinger

- 13** ANTITUMOR METALLODRUGS THAT TARGET PROTEINS — **351**
 - Abstract — **352**
 - 1. Introduction — **352**
 - 2. Anticancer Metallodrugs that Target Carrier Proteins — **354**
 - 3. Selected Cancer-Related Proteins as Targets — **362**
 - 4. Non-Conventional Protein Targets for Anticancer Metallodrugs — **373**
 - 5. Modern Bioanalytical Methods — **375**
 - 6. Concluding Remarks and Future Directions — **376**
 - Acknowledgments — **377**
 - Abbreviations — **377**
 - References — **379**

Ulrich Schatzschneider

- 14** METALLOINTERCALATORS AND METALLOINSERTORS:
STRUCTURAL REQUIREMENTS FOR DNA RECOGNITION AND
ANTICANCER ACTIVITY — **387**
 - Abstract — **388**
 - 1. Introduction — **388**
 - 2. The Basics: Nucleic Acid Structure and Enzymatic Processing — **389**
 - 3. Analytical Methods to Study Metal Complex-DNA Interactions — **394**
 - 4. Metallointercalators — **396**
 - 5. Metalloinsertors — **413**
 - 6. Concluding Remarks and Future Directions — **426**
 - Abbreviations and Definitions — **427**
 - References — **430**

Frank Thévenod

15 IRON AND ITS ROLE IN CANCER DEFENSE: A DOUBLE-EDGED SWORD — 437

Abstract — **438**

1. Introduction — **438**

2. Short Overview of Systemic and Cellular Iron Homeostasis — **439**

3. Iron and Cancer Formation: “A Predominant Feature” — **441**

4. Iron and Cancer Defense: “Long Live the Difference” — **444**

5. General Conclusions — **456**

Acknowledgments — **456**

Abbreviations and Definitions — **456**

References — **458**

Delphine Denoyer, Sharnel A. S. Clatworthy, and Michael A. Cater

16 COPPER COMPLEXES IN CANCER THERAPY — 469

Abstract — **470**

1. Introduction — **470**

2. Repurposing Old Copper Complexes for Cancer Treatment — **477**

3. Emerging Classes of Copper Complexes for Cancer Treatment — **489**

4. General Conclusions — **496**

Acknowledgments — **497**

Abbreviations — **497**

References — **498**

Silvia Ziliotto, Olivia Ogle, and Kathryn M. Taylor

17 TARGETING ZINC(II) SIGNALLING TO PREVENT CANCER — 507

Abstract — **507**

1. Introduction — **508**

2. Zinc Handling in Cells — **508**

3. Zinc in Cancer — **513**

4. Zinc Signalling in Cancer — **518**

5. Targeting Zinc Signalling Mechanisms in Cancer — **520**

6. General Conclusions — **523**

Acknowledgments — **523**

Abbreviations and Definitions — **524**

References — **524**

SUBJECT INDEX — 531